News

Important milestone in managing adherence to anti-osteoporosis treatment

AARDEX’s scientific lead Bernard Vrijens is a co-author of the new publication in the Osteoporosis International journal about determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment.

This video shows how to speed up your drug development.

Discover why the Pharmaceutical world trusts us to resolve patient non-compliance.

AARDEX Group is invited as a guest speaker at the 2019 European Respiratory Society (ERS)

Bernard Vrijens, CEO of AARDEX Group, is invited as a guest speaker at the 2019 annual meeting of the ERS, Madrid, Spain, September 30, 2019.

A Six Sigma framework to successfully manage medication adherence

Discover our CEO’s last publication in the British Journal of Clinical Pharmacology

AARDEX Group will be at BIO International Convention (3-6 June, 2019)

AARDEX Group, the leader in medication adherence monitoring and management

AARDEX Group is invited as a guest speaker at the 2019 ASCPT

Bernard Vrijens, CEO of AARDEX Group, is invited as a guest speaker at the 2019

AARDEX leading position in the B2B medication adherence market

AARDEX still confirms its leading position in the B2B medication adherence market

AARDEX solutions facilitate the NARC Non-adherence classification in clinical trials

DEC-2018 : Electronic compilation of drug dosing history data using MEMS®